Clinical pharmacokinetics of darunavir (Q36916791)

17 August 2017

1 reference

title

Clinical pharmacokinetics of darunavir (English)

1 reference

17 August 2017

1 reference

2

Keikawus Arastéh

0 references

author name string

Michael Rittweger

series ordinal

1

1 reference

17 August 2017

Keikawus Arastéh

series ordinal

2

1 reference

17 August 2017

publication date

1 January 2007

1 reference

Clinical Pharmacokinetics

17 August 2017

published in

1 reference

17 August 2017

volume

46

1 reference

17 August 2017

issue

9

1 reference

17 August 2017

page(s)

739-756

1 reference

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

17 August 2017

cites work

1 reference

12 December 2020

Safety of HMG-CoA reductase inhibitors: focus on atorvastatin

1 reference

12 December 2020

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

1 reference

12 December 2020

Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment

1 reference

12 December 2020

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

1 reference

12 December 2020

Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

1 reference

12 December 2020

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450

1 reference

12 December 2020

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

12 December 2020

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor

1 reference

12 December 2020

Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia

1 reference

12 December 2020

The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients

1 reference

12 December 2020

Paroxetine plasma levels: lack of correlation with efficacy or adverse events

1 reference

12 December 2020

Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance

1 reference

12 December 2020

Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

1 reference

12 December 2020

Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

1 reference

12 December 2020

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

12 December 2020

Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers

1 reference

12 December 2020

A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects

1 reference

12 December 2020

Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor

1 reference

12 December 2020

Sertraline 50 mg daily: the optimal dose in the treatment of depression

1 reference

12 December 2020

The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.

1 reference

12 December 2020

Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital

1 reference

12 December 2020

Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers

1 reference

12 December 2020

Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir

1 reference

12 December 2020

Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.

1 reference

12 December 2020

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy

1 reference

12 December 2020

10.2165/00003088-200746090-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

17 August 2017

1017212433

0 references

1 reference